Loria-Castellanos J, Cerón-Apipilhuasco A, Mandujano MD

Language: Spanish
References: 14
Page: 126-130
PDF size: 185.79 Kb.

ABSTRACT

Opioid addiction is a public health crisis due to its easy access, addictive effects, and high mortality, compounded by the lack of immediate access to antagonists and limited knowledge regarding treatment dosage in cases of intoxication. The management of these patients must be gradual to avoid withdrawal syndrome, its adverse effects, and consequently the increase in mortality and hospital discharge against medical advice. Strategies have been implemented by the United States government—one of the countries most affected—for the acute management of patients; however, limited training and community willingness remain major barriers to the success of these programs.

REFERENCES

1. Zhang JJ, Song CG, Dai JM, Li L, Yang XM, Chen ZNMechanismof opioid addiction and its intervention therapy: Focusing on thereward circuitry and mu-opioid receptor. MedComm; .(2020),3(3):e148.

2. CDC’s Drug Overdose Deaths .(2023) https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#:~:text=Overall%2C%20drug%20overdose%20deaths%20rose,overdose%20deaths%20reported%20in%202021

3. Zang, X., Skinner, A., Krieger, M. S., Behrends, C. N., Park, J.N., Green, T. C., Walley, A. Y., Morgan, J. R., Linas, B. P., Yedinak,J. L., Schackman, B. R., & Marshall, B. D. L. Evaluation ofStrategies to Enhance Community-Based Naloxone DistributionSupported by an Opioid Settlement. JAMA network open, (2024).7(5), e2413861.

4. Popper C, Kelen GD, Cunningham G, Peligro de naloxona en elabuso de drogas. Lanceta ; (1989). 2(8660):446.

5. Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K.(2016) Sobredosis no fatal como factor de riesgo de sobredosisfatal posterior entre personas que se inyectan drogas. Dependenciadel alcohol de las drogas;162:51-5

6. Saari, T. I., Strang, J., & Dale, O. Clinical Pharmacokinetics andPharmacodynamics of Naloxone. Clinical pharmacokinetics,(2024). 63(4), 397–422. https://doi.org/10.1007/s40262-024-01355-6

7. Mahonski, S. G., Leonard, J. B., Gatz, J. D., Seung, H., Haas, E.E., & Kim, H. K. Prepacked naloxone administration for suspectedopioid overdose in the era of illicitly manufactured fentanyl: A retrospectivestudy of regional poison center data. Clinical Toxicology.(2019). https://doi.org/10.1080/15563650.2019.1615622

8. Choi, N. G., Choi, B. Y., DiNitto, D. M., Marti, C. N., & Baker, S. D.Naloxone therapy for prescription and illicit opioid poisoning casesaged 50+ in the national poison data system, 2015–2020. ClinicalToxicology, (2022). 60(4), 499–506. https://doi.org/10.1080/15563650.2021.1981362

9. Comisión Nacional de Salud Mental y Adicciones (CONASAMA).(2024, abril 8). Alerta para personal de salud y primeros respondientesde ciudades fronterizas de México por posible presenciade xilacina en opioides (SAT-OMSA). https://www.gob.mx/ Gobiernode México

10. The U.S. FDA. (2023, 29 marzo). La FDA aprueba el primer aerosolnasal de naloxona de venta libre (Narcan 4 mg). U.S. Foodand Drug Administration

11. Shaw LV, Moe J, Purssell R, Buxton JA, Godwin J, Doyle-WatersMM, Brasher PMA, Hau JP, Curran J, Hohl CM. Intervencionescon naloxona en sobredosis de opioides: un protocolo de revisiónsistemática. Syst Rev; (2019), (1):138.

12. Gupta, R., Shah, N. D., & Ross, J. SThe rising price of naloxone—Risks to efforts to stem overdose deaths. New England Journal ofMedicine, . (2016). 375(23), 2213–2215. https://doi.org/10.1056/NEJMp1610839

13. Romero, R. B., et al. (2023). Implementing a decentralized opioidoverdose prevention strategy in Mexico’s northern border. LancetRegional Health – Americas. (Resumen de acceso abierto). ScienceDirect

14. Joseph, M., Amin, K., Siddens, C., Jaime, G., Seeger, C. M., Mercer,K., & Chau, T. Pulmonary edema after naloxone administrationfor opioid reversal: A systematic review of case reports andcausality assessment using the Naranjo scale. Clinical Toxicology,(2024). 62(5), 334–342. https://doi.org/10.1080/15563650.2024.2348108